Patents by Inventor Kerstin Westritschnig

Kerstin Westritschnig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20230173052
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: September 9, 2022
    Publication date: June 8, 2023
    Applicants: VALNEVA AUSTRIA GMBH, VALNEVA USA, INC.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 11478540
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: October 25, 2022
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 11357844
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: June 14, 2022
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20210393761
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: August 19, 2021
    Publication date: December 23, 2021
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20210121554
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: October 2, 2020
    Publication date: April 29, 2021
    Applicants: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 10821166
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: November 3, 2020
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20190290747
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: March 7, 2019
    Publication date: September 26, 2019
    Applicant: Valneva Austria GmbH
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 10357557
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: July 23, 2019
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20170239340
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 24, 2017
    Applicants: Valneva Austria GmbH, Intercell USA, Inc.
    Inventors: LARRY R. ELLINGSWORTH, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 9598472
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: September 5, 2011
    Date of Patent: March 21, 2017
    Assignees: Valneva Austria GmbH, Intercell USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • VACCINE CARRIER
    Publication number: 20160257722
    Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.
    Type: Application
    Filed: December 17, 2015
    Publication date: September 8, 2016
    Applicant: BIOMAY AG
    Inventors: Rudolf VALENTA, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Renate Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Gronlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
  • Vaccine carrier
    Patent number: 9296828
    Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: March 29, 2016
    Assignee: BIOMAY AG
    Inventors: Rudolf Valenta, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Peter Valent, Renate Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Grönlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20150056238
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: September 5, 2011
    Publication date: February 26, 2015
    Applicants: Intercell USA, Inc., Valneva Austria GmbH
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • OprF/I AGENTS AND USE THEREOF IN HOSPITALIZED AND OTHER PATIENTS
    Publication number: 20130266575
    Abstract: The present invention relates to a new use of a vaccine comprising a fusion protein that comprises the Pseudomonas aeruginosa outer membrane protein I (OprI or OMPI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF or OMPF), as well as to a new use of a monoclonal or polyclonal antibody against this fusion protein or a pharmaceutical composition thereof.
    Type: Application
    Filed: March 12, 2013
    Publication date: October 10, 2013
    Inventors: Christoph Klade, Robert Schlegl, Kerstin Westritschnig
  • S. AUREUS ALLERGEN
    Publication number: 20120171238
    Abstract: The invention discloses the use of a protein with an amino acid sequence according to SEQ. ID. NO. 1 or a naturally occurring fragment or variant thereof for identifying infections with S. aureus in a human sample. More specifically, IgE molecules specific for SEQ. ID. NO. 1 are detected in the sample of the patient. Many atopic dermatitis patients have IgE specific for SEQ. ID. NO. 1.
    Type: Application
    Filed: September 10, 2010
    Publication date: July 5, 2012
    Applicant: BIOMAY AG
    Inventors: Rudolf Valenta, Kavita Reginald, Kerstin Westritschnig, Birgit Linhart, Angelika Stöcklinger, Josef Thalhamer, Alexander M. Hirschi, Thomas Werfel, Elli Greisenegger, Tamara Kopp
  • Vaccine Carrier
    Publication number: 20090324501
    Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.
    Type: Application
    Filed: June 11, 2007
    Publication date: December 31, 2009
    Applicant: Biomay AG
    Inventors: Rudolf Valenta, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Peter Valent, Renat Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Grönlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
  • HYPOALLERGENIC ALLERGY VACCINES BASED ON THE TIMOTHY GRASS POLLEN ALLERGEN PHL P 7
    Publication number: 20090074801
    Abstract: The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for the treatment of sensitized allergic patients and for prophylactic vaccination.
    Type: Application
    Filed: August 11, 2008
    Publication date: March 19, 2009
    Applicant: BIOMAY Produktions-und Handels-Aktiengesellschaft
    Inventors: Kerstin WESTRITSCHNIG, Margarete Focke, Anna Twardosz, Peter Valent, Petra Verdino, Walter Keller, Dietrich Kraft, Rudolf Valenta
  • Protein Allergen Derivatives
    Publication number: 20080286311
    Abstract: The present invention relates to a method for producing derivatives of wild-type protein allergens with reduced allergenic activity, characterized in by the following steps: providing a wild-type protein allergen with an allergenic activity, splicing said wild-type protein allergen into two parts, said two parts having a reduced allergenic activity or lacking allergenic activity and rejoining said two fragments in inverse orientation; as well as allergen derivatives.
    Type: Application
    Filed: December 2, 2005
    Publication date: November 20, 2008
    Applicant: BIOMAY AG
    Inventors: Kerstin Westritschnig, Margarete Focke, Peter Valent, Walter Keller, Rudolf Valenta
  • Hypoallergenic allergy vaccines based on the timothy grass pollen allergen Phl p 7
    Patent number: 7425333
    Abstract: The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: September 16, 2008
    Assignee: Biomay Produktions-und Handels-Aktiengesellschaft
    Inventors: Kerstin Westritschnig, Margarete Focke, Anna Twardosz, Peter Valent, Petra Verdino, Walter Keller, Dietrich Kraft, Rudolf Valenta
  • Hypoallergenic allergy vaccines based on the timothy grass pollen allergen phl p7
    Publication number: 20060216314
    Abstract: The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phi p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.
    Type: Application
    Filed: September 25, 2003
    Publication date: September 28, 2006
    Applicant: BIOMAY PRODUKTIONS- UND HANDELS-AKTIENGESELLSCHAFT
    Inventors: Kerstin Westritschnig, Margarete Focke, Anna Twardosz, Peter Valent, Petra Verdino, Walter Keller, Dietrich Kraft, Rudolf Valenta